Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings
CNBC Earnings
Barrons Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

Stocktwits
MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-

Dianthus Therapeutics, Inc. Common Stock | DNTH

AI Analysis of Dianthus Therapeutics, Inc. Common Stock

Not too much action today, Dianthus Therapeutics drifted down slightly. We'll see where it goes next. It looks like DNTH could be hitting an upward sloping resistance line. Most traders won't try to short a stock when the line is upsloping. But it may be a good time to take profit or wait for a better entry point for a long position. Let's also consider momentum! Dianthus Therapeutics has been on a tear lately and has decent upward momentum, when assets move up like that, they have a habit of breaking through resistance points. so unless you know something I don't, it probably wouldn't short a stock like this. Year over year, the asset has returned 376.69 percent to its shareholders.

If it breaks through the resistance level, we aren't seeing any clear resistance points beyond that. So it may have plenty of room to work up from there. If the price reverses and heads back down lower, it looks like the nearest support level is $72.9 it may head back up from there or break lower.


Last analyzed on 2026-07-23

Research

Estimates

SA Earngings
MB Earnings
Yahoo Earnings

Ratings

SA Ratings
MB Ratings
BC Ratings
TR Ratings
Fidelity

Short Interest

MB Shorts
Quandl

Smart Money

MB Institutional
Gurus

Options

BC Options Ratio

Financials

GuruFocus Summary

Social

MB Social
SocialSentiment.com
Twitter
Yahoo
Facebook
Reuters
Google

Misc

Tickeron
Ycharts NAV +/-